Small intestinal bacterial overgrowth (SIBO) occurs when colon-specific bacteria proliferate in the small intestine, disrupting digestion and nutrient absorption [1]. Once considered a rare malabsorption condition, SIBO is now recognized as a common contributor to bloating, abdominal pain, and altered bowel habits—symptoms that often overlap with irritable bowel syndrome (IBS) [8].
Research estimates SIBO affects 2.5-22% of the general population, though prevalence varies widely depending on the population studied and diagnostic methods used [1]. Understanding the causes, proper testing approaches, and dietary management strategies is essential for those experiencing persistent digestive symptoms.
Key takeaways
- SIBO involves bacterial overgrowth in the small intestine, distinct from colonic flora, with E. coli and Klebsiella being predominant species [2].
- Breath testing (hydrogen/methane) is the primary non-invasive diagnostic tool, though protocols vary and overdiagnosis is a concern [14].
- Dietary approaches like low-FODMAP can help manage symptoms by reducing fermentable substrates [10].
- SIBO prevalence is higher in patients with metabolic liver disease (66%), systemic sclerosis, and other chronic conditions [7][11].
- Successful management requires addressing underlying causes, not just treating symptoms [8][11].
What Causes SIBO?
SIBO develops when the delicate balance between gut motility, intestinal architecture, and microbial ecology breaks down [15]. Several factors can contribute to this disruption:
- Impaired motility: Conditions that slow intestinal transit allow bacteria to accumulate. This includes motility disorders and systemic diseases like systemic sclerosis, where fibrosis and dysbiosis promote microbial stasis [11].
- Anatomical changes: Previous abdominal surgeries, diverticula, or structural abnormalities can create pockets where bacteria flourish.
- Underlying conditions: SIBO is particularly common in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with prevalence reaching 66.3% in one large study [7]. Risk factors include advanced fibrosis, gastroesophageal reflux disease (GERD), and coronary artery disease [7].
- Connective tissue disorders: Conditions like hypermobile Ehlers-Danlos syndrome (hEDS) frequently present with SIBO due to gastrointestinal motility issues [16].
Recent advances using next-generation sequencing have revealed that SIBO typically involves overgrowth of Proteobacteria species, specifically Escherichia coli and Klebsiella, rather than a migration of colonic flora into the small intestine [2].
How Is SIBO Diagnosed?
Two primary diagnostic approaches exist for SIBO testing:
- Breath testing: The most common non-invasive method measures hydrogen and methane produced by bacterial fermentation after consuming a substrate like lactulose or glucose [5]. A rise in breath hydrogen or methane above established thresholds (typically >20 ppm above baseline) suggests bacterial overgrowth [9]. Breath testing has been validated against small bowel microbiome analysis [2].
- Small bowel aspiration: Direct sampling via endoscopy allows culturing of intestinal fluid, but this invasive approach has limited clinical availability and carries risks [6].
It's important to note that breath testing protocols vary significantly across centers, and experts advocate for a cautious approach to diagnosis given concerns about overdiagnosis, particularly when using lactulose substrates [14]. The Asian Neurogastroenterology and Motility Association has published guidance to standardize testing protocols and interpretation criteria [5].
In pediatric cases, hydrogen breath testing with lactulose confirmed diagnosis, with treatment leading to symptom resolution [4].
Dietary Approaches for SIBO Management
Dietary modification is a cornerstone of SIBO management, focusing on reducing fermentable substrates that feed overgrown bacteria:
- Low-FODMAP diet: This approach restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols—carbohydrates that bacteria ferment producing gas. While not specifically designed for SIBO, it shares evidence with IBS management where SIBO often co-occurs [10].
- Elemental diets: Specialized liquid formulas providing easily absorbed nutrients can starve bacterial overgrowth while maintaining nutrition.
- Targeted elimination: Some patients benefit from identifying specific food intolerances. Research on functional bloating found fructose malabsorption in 29% of patients with bloating, compared to just 3% in healthy controls [9].
Beyond restriction, emerging evidence supports microbiome-targeted approaches including probiotics and prebiotics, though outcomes remain variable across studies [8][11]. A terrain-based recovery protocol addressing microbiome restoration showed promising results in a case of SIBO with multiple systemic symptoms [12].
Treatment Considerations Beyond Diet
While this article focuses on diet, understanding the full treatment landscape is important:
- Antibiotics: Rifaximin is commonly prescribed for SIBO, particularly in IBS-overlap cases [10]. However, concerns about antibiotic resistance, microbiome disruption, and relapse have driven interest in non-antibiotic strategies [8].
- Prokinetics: Medications or supplements that improve gut motility may help prevent recurrence, especially in conditions like systemic sclerosis where motility is inherently impaired [11].
- Addressing root causes: Successful management requires treating underlying conditions—whether GERD, liver disease, or connective tissue disorders [7][16].
Given the complex pathophysiology of bloating, which involves gas production, visceral hypersensitivity, and altered gut-brain axis signaling [3], a personalized approach considering individual patient factors is essential.
When to Seek Testing
Consider SIBO testing if you experience:
- Persistent bloating, particularly after meals
- Abdominal discomfort or pain
- Altered bowel habits (diarrhea, constipation, or alternating)
- Unexplained nutrient deficiencies, particularly vitamin B12 [1]
- Symptoms that haven't responded to standard digestive treatments
Because SIBO symptoms overlap with many other conditions—including IBS, fructose malabsorption, and celiac disease—thorough evaluation is important [9]. Testing is particularly warranted in patients with known risk factors like liver disease, autoimmune conditions, or history of abdominal surgery [7][11].
Frequently asked questions
Can SIBO be cured with diet alone?
Dietary modifications can significantly reduce symptoms and bacterial overgrowth, but successful management often requires addressing underlying causes like motility issues or anatomical problems. Many patients benefit from combined approaches including diet, antibiotics when indicated, and prokinetics [8][11].
What is the difference between SIBO and IMO?
Intestinal methanogen overgrowth (IMO) involves excessive methane-producing archaea (primarily Methanobrevibacter smithii) rather than bacteria [1]. IMO is associated with constipation-predominant presentations, while hydrogen-producing SIBO often correlates with diarrhea and bloating [8].
How accurate is breath testing for SIBO?
Breath testing offers moderate sensitivity and specificity and has been validated against small bowel microbiome analysis [2][11]. However, protocol variability and concerns about overdiagnosis with lactulose-based tests warrant cautious interpretation [14]. Modern concepts now recognize three overgrowth types: SIBO, IMO, and intestinal sulfide overproduction (ISO) [2].
Does SIBO cause vitamin deficiencies?
Yes, SIBO can impair absorption of essential nutrients including vitamin B12 and fat-soluble vitamins, potentially leading to malnutrition [1]. This is particularly relevant in cancer patients and those with underlying conditions affecting nutrient status.
Are probiotics helpful for SIBO?
Probiotic and prebiotic approaches show variable outcomes in SIBO management [8][11]. While some patients benefit, evidence remains heterogeneous, and inappropriate use may worsen symptoms in certain cases. Working with a healthcare provider is recommended.
References
- Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies — Mechlińska A et al., 2025, Contemporary oncology (Poznan, Poland)
- Modern concepts of small intestinal bacterial overgrowth — Barlow GM et al., 2025, Current opinion in gastroenterology
- Constipation with bloating: a clinical approach to evaluation and management — Cangemi DJ et al., 2026, Annals of medicine
- Difficulties in diagnosing a pediatric patient with small intestinal bacterial overgrowth — Tuñas LC et al., 2026, Einstein (Sao Paulo, Brazil)
- Hydrogen and Methane Breath Test: The Asian Neurogastroenterology and Motility Association Monograph — Xiao Y et al., 2026, Journal of neurogastroenterology and motility
- Unraveling the Complexities of Small Intestinal Bacterial Overgrowth — Capuano E et al., 2026, Medicina (Kaunas, Lithuania)
- Small Intestinal Bacterial Overgrowth in Metabolic Dysfunction-Associated Steatotic Liver Disease: Prevalence, Subtypes, and Risk Factors Across Disease Spectrum and Comorbidity Profiles — Li Y et al., 2026, Biomedicines
- IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions — Šuran J et al., 2026, Antibiotics (Basel, Switzerland)
- Fructose malabsorption associated with functional abdominal bloating: Case-control study — Kulandaivelu A et al., 2026, World journal of gastrointestinal pharmacology and therapeutics
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications — Pastras P et al., 2026, Pharmaceuticals (Basel, Switzerland)
- Eradication of Small Intestinal Bacterial Overgrowth in Systemic Sclerosis: Current Treatment and Perspectives-A Narrative Review — Radić M et al., 2025, Biomedicines
- Self-Directed Recovery of Gu Syndrome: Reversal of Multisystem Dysfunction via Microbiome Restoration and Subconscious-Guided Protocols — Chohan PK et al., 2025, Cureus
- Prevalence and Risk Factors of Celiac Disease in Patients With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis — Keetha NR et al., 2026, JGH open : an open access journal of gastroenterology and hepatology
- Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth: Are They Overdiagnosed? — Kholwadwala AS et al., 2025, Acta gastroenterologica Latinoamericana
- Small intestinal microbiome, the underrated maestro of SIMO disease — Deschamps C et al., 2026, FEMS microbiology reviews
- Hypermobile Ehlers-Danlos Syndrome With Prominent Gastrointestinal and Autonomic Involvement in a Latin American Patient: A Case Report — Chavarría-Aguilar S et al., 2025, Cureus